medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-1-18(393)-39-43medalphabet-1270Research ArticleСтатьиБезопасность инфликсимаба в условиях реальной клинической практикиSafety of infliximab in real clinical practiceАроноваЕ. С.AronovaE. S.

к. м. н., н. с. лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии

г. Москва

Moscow

ЛукинаГ. В.LukinaG. V.

д. м. н., проф., зав. научно-исследовательским отделом ревматологии

г. Москва

Moscow

ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»; ГБУЗ «Московский клинический научно-практический центр имени А. С. Логинова» Департамента здравоохранения г. МосквыРоссияV.A. Nasonova Research Institute of Rheumatology; A. S. Loginov Moscow Clinical Scientific CenterRussian Federation201926112019118Ревматология в общей врачебной практике3943Copyright © Аронова Е.С., Лукина Г.В., 20192019Аронова Е.С., Лукина Г.В.Aronova E.S., Lukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1270

Широкий спектр высокоэффективных генно‑инженерных биологических препаратов, введенных в клиническую ревматологию за последние годы, обусловливает особый интерес к их безопасности.

Цель исследования

Цель исследования. Оценка безопасности терапии инфликсимабом у больных ревматоидным артритом.

Материал и методы

Материал и методы. Изложены собственные данные авторов, проанализировавших нежелательные эффекты инфликсимаба у 135 больных ревматоидным артритом в реальной клинической практике. Представлено собственное наблюдение случая побочной реакции комбинированной терапии лефлуномидом и инфликсимабом.

Результаты и их обсуждение. Общая переносимость инфликсимаба была удовлетворительной. Нежелательные явления отмечались в 28,1 % случаев, в том числе у 19,1 % пациентов (14,1 %) наблюдались серьезные побочные эффекты, потребовавшие отмены препарата.

Выводы

Выводы. В большинстве случаев инфликсимаб безопасен для применения в реальной клинической практике. Перед назначением терапии следует информировать пациентов о рисках возникновения нежелательных эффектов и необходимости осмотра ревматологом перед каждым введением инфликсимаба.

A wide range of highly effective genetically engineered biological preparations introduced into clinical rheumatology in recent years causes a special interest in their safety.

Purpose of the study

Purpose of the study. Evaluation of the safety of infliximab therapy in patients with rheumatoid arthritis.

Materials and methods

Materials and methods. The authors' own data, which analyzed the undesirable effects of infliximab in 135 patients with rheumatoid arthritis in actual clinical practice, are presented. A case report of the adverse reaction of combination therapy with leflunomide and infliximab is presented.

Results and its discussion. The overall tolerability of infliximab was satisfactory. Adverse events were observed in 28.1 % of cases, including 19.1 % of patients (14.1 %) had serious side effects that required discontinuation of the drug.

Findings

Findings. In most cases, infliximab is safe for use in actual clinical practice. Patients should be informed about the risks of undesirable effects and the need for a rheumatologist's examination before each infliximab administration before prescribing therapy.

биологическая терапиягенно‑инженерные биологические препаратыинфликсимабингибиторы ФНО‑αнеблагоприятные реакцииревматоидный артритbiological therapygenetic engineering biologicalsinfliximabTNF‑α inhibitorsadverse reactionsrheumatoid arthritisReferencesЛукина Г. В., Сигидин Я. А., Чичасова Н. В., Балабанова Р. М., Беленький А. Г. и соавт. Применение моноклональных антител к фактору некроза опухоли (Ремикейд) при ревматоидном артрите: предварительные результаты. Тер. архив, 2003, Т. 75, № 5, С. 9–12.Лукина Г. В., Сигидин Я. А., Чичасова Н. В., Балабанова Р. М., Беленький А. Г. и соавт. Применение моноклональных антител к фактору некроза опухоли (Ремикейд) при ревматоидном артрите: предварительные результаты. Тер. архив, 2003, Т. 75, № 5, С. 9–12.Cozzani E, Larosa M, Parodi A. Skin manifestations associated with anti TNF-α therapy. Clinical Dermatology. 2013 April-June; 2 (2): 67–71. ISSN: 2282–4103.Cozzani E, Larosa M, Parodi A. Skin manifestations associated with anti TNF-α therapy. Clinical Dermatology. 2013 April-June; 2 (2): 67–71. ISSN: 2282–4103.Collamer AN, Battafarano DF. Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis. Semin Arthritis Rheum. 2010 Jun 25. [Epub ahead of print]Collamer AN, Battafarano DF. Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis. Semin Arthritis Rheum. 2010 Jun 25. [Epub ahead of print]Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009 Nov; 102 (11): 1133–40.Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009 Nov; 102 (11): 1133–40.Lodhi RL, Shubhini AS, Gaurav K et al. Pharmacology and toxicology of leflunomide. Iranian Journal of Pharmacology and Therapeutist. Jan. 2012, Vol. 11, No. 1, 26–32.Lodhi RL, Shubhini AS, Gaurav K et al. Pharmacology and toxicology of leflunomide. Iranian Journal of Pharmacology and Therapeutist. Jan. 2012, Vol. 11, No. 1, 26–32.Van Riel P. Insights from Dutch DMARD and biological registries. In: Rheumatoid arthritis: optimizing management trough education. Abstr. Book, 17–18 March 2007, Vienna, Austria; p. 16–17.Van Riel P. Insights from Dutch DMARD and biological registries. In: Rheumatoid arthritis: optimizing management trough education. Abstr. Book, 17–18 March 2007, Vienna, Austria; p. 16–17.Singh JA, Wells GA, Christensen R et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2016, Issue 5.Singh JA, Wells GA, Christensen R et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2016, Issue 5.Лукина Г. В., Сигидин Я. А., Позднякова Е. С. и соавт. Инфликсимаб в Российской клинической практике. Современная ревматология, 2012, т. 6, № 3, с. 37–43.Лукина Г. В., Сигидин Я. А., Позднякова Е. С. и соавт. Инфликсимаб в Российской клинической практике. Современная ревматология, 2012, т. 6, № 3, с. 37–43.Сигидин Я. А., Лукина Г. В. Биологическая терапия в ревматологии. — 2-е изд., доп. М.: Практическая медицина, 2009. — с. 64.Сигидин Я. А., Лукина Г. В. Биологическая терапия в ревматологии. — 2-е изд., доп. М.: Практическая медицина, 2009. — с. 64.Bernatsky S, Habel Y, Rahme E. Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists. J Rheumatol. 2010 Apr 1. [Epub ahead of print]Bernatsky S, Habel Y, Rahme E. Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists. J Rheumatol. 2010 Apr 1. [Epub ahead of print]Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; on behalf of the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2010 Jul 31. [Epub ahead of print]Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; on behalf of the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2010 Jul 31. [Epub ahead of print]Leombruno J. The challenges of quantifying the risk of serious infection with tumor necrosis factor antagonist therapy. J Rheumatol. 2010 May; 37 (5): 887–9.Leombruno J. The challenges of quantifying the risk of serious infection with tumor necrosis factor antagonist therapy. J Rheumatol. 2010 May; 37 (5): 887–9.Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol. 2010 May; 37 (5): 928–31. Epub 2010. Apr 1.Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol. 2010 May; 37 (5): 928–31. Epub 2010. Apr 1.Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011, Dec 7; 306 (21): 2331–9.Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011, Dec 7; 306 (21): 2331–9.Hongxing Liao, Zhixiong Zhong, Zhanliang Liu and Xuenong Zou. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. International Journal of Rheumatic Diseases 2017; 20: 161–168.Hongxing Liao, Zhixiong Zhong, Zhanliang Liu and Xuenong Zou. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. International Journal of Rheumatic Diseases 2017; 20: 161–168.Kharbanda P, Dagaonkar R, Balakrishnan C, Udwadia ZF. Tumor necrosis factor-alpha blocker induced tuberculosis. J Rheumatol. 2010 Jul; 37 (7): 1542; author reply 1543.Kharbanda P, Dagaonkar R, Balakrishnan C, Udwadia ZF. Tumor necrosis factor-alpha blocker induced tuberculosis. J Rheumatol. 2010 Jul; 37 (7): 1542; author reply 1543.Girlanda S, Mantegani P, Baldissera E, Aiello P, Ratti M, Sabbadini MG, Fortis C. ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment. Clin Rheumatol. 2010 Oct; 29 (10): 1135–41. Epub 2010. Jul 20.Girlanda S, Mantegani P, Baldissera E, Aiello P, Ratti M, Sabbadini MG, Fortis C. ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment. Clin Rheumatol. 2010 Oct; 29 (10): 1135–41. Epub 2010. Jul 20.Reenaers C, Belaiche J, Louis E. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflamm Bowel Dis. 2010 Aug; 16 (8): 1271–2.Reenaers C, Belaiche J, Louis E. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflamm Bowel Dis. 2010 Aug; 16 (8): 1271–2.Malaviya AN, Kapoor S, Garg S, Rawat R. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India — followup report. J Rheumatol. 2010 Jan; 37 (1): 209.Malaviya AN, Kapoor S, Garg S, Rawat R. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India — followup report. J Rheumatol. 2010 Jan; 37 (1): 209.Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Research & Therapy 2010, 12: 103.Jansen TL. When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers? Arthritis Research & Therapy 2010, 12: 103.Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, BritoZerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011 Nov; 90 (6): 359–71.Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, BritoZerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011 Nov; 90 (6): 359–71.Shunsuke Mori, Shigetoshi Fujiyama. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015 Sep 28; 21 (36): 10274–10289.Shunsuke Mori, Shigetoshi Fujiyama. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol. 2015 Sep 28; 21 (36): 10274–10289.Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010; 29: 1021–1029.Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010; 29: 1021–1029.Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun; 62 (6): 749–54.Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun; 62 (6): 749–54.Maurizio Pompili, Marco Biolato, Luca Miele, Antonio Grieco. Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. Clin Gastroenterol Hepatol. 2013 May; 11 (5): 558–564.Maurizio Pompili, Marco Biolato, Luca Miele, Antonio Grieco. Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. Clin Gastroenterol Hepatol. 2013 May; 11 (5): 558–564.Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum 2010; 62 (11): 3191–3195.Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum 2010; 62 (11): 3191–3195.Summut L, Wallis D, Holroyd C. Progressive multifocal leukoencephalopathy associated with infliximab. J R Coll Physicians Edinb. 2016 Sep; 46 (3): 163–165.Summut L, Wallis D, Holroyd C. Progressive multifocal leukoencephalopathy associated with infliximab. J R Coll Physicians Edinb. 2016 Sep; 46 (3): 163–165.

The authors declare that there are no conflicts of interest present.